All News
A claims cohort comparison of #RA pts with H.zoster (n 1 866 ) and pts without HZ (38,846). RA+/HZ+ pts had significantly greater Hospitalizations, emergency visits (esp <30d post HZ Dx; adj IRR hosp=3.4; ED=3.7) and higher Total HC costs https://t.co/89GLUK93dO https://t.co/9jweduoBHw
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for:
-KOL perspective videos
-Clinical Trial Highlights
-Daily Faculty Recaps
-Live Streaming
and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
Join us for the final Tuesday Night Rheumatology of May.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Methotrexate Use: 50 Yr. Perspective
Myths vs Reality in RA
Biosimilars - Back on the Agenda
https://t.co/0OenWkXarV https://t.co/yUHwslkZ9o
Links:
Dr. John Cush RheumNow ( View Tweet)
3-4-5 Rule
Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on https://t.co/V10S4oVFsv
https://t.co/4iQERIh5Zl https://t.co/bwSk9L7ucC
Dr. John Cush RheumNow ( View Tweet)
⚠️Beware not all bone marrow oedema =#AxSpA on MRI !
Signal seen in 17% volunteers at SIJs
@DrPoddubnyy
#RNL2023 https://t.co/xTKuSRXK72 https://t.co/c09QjSkJBP
Links:
Dr. John Cush RheumNow ( View Tweet)
FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women
https://t.co/8tc51AJ14n https://t.co/lhF7iwl0N3
Links:
Dr. John Cush RheumNow ( View Tweet)
With all the new adalimumab biosimilars happening in 2023, where's the pen? Now the FDA has approved an ADA biosimilar, Cyltezo, Autoinjector Pen! https://t.co/TgsA46xGsv https://t.co/rXcRcp7tDX
Links:
Dr. John Cush RheumNow ( View Tweet)
Dennis Poddubnyy #RNL2023
MRI sequences for axSpA:
Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression
Semi-axial- T2 STIR
@RheumNow https://t.co/aidLu7GcQH https://t.co/YOrboYl6pW
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: GPA Treatment Choices
https://t.co/9v6C5nOLqu https://t.co/1E347ulsvR
Links:
Dr. John Cush RheumNow ( View Tweet)
Colchicine does not work in Hand OA. Danish trial of 100 HOA pts (age 71 yrs) given placebo or COL 0.5 mg bid x 12wk. Finger pain improved –13·9 mm w/ colchicine vs –13·5 mm w/ PBO (NS). More adverse events w/ Colchicine (72% vs 44%) https://t.co/042BQcAFWf https://t.co/EldLmjVisD
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS.
*Erosions in 3 or more SIJ quadrants
*BME in 4 or more SIJ quadrants
*Fat lesions in 5 of more SIJ quadrants
#RNL2023 @RheumNow https://t.co/T9iWLcNL8b https://t.co/BskCNz9Klj
Links:
Dr. John Cush RheumNow ( View Tweet)
Peresolimab's Potential in Rheumatoid Arthritis
Peresolimab is a humanized IgG1 monoclonal antibody that acts as a PD-1 agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active RA.
https://t.co/tBAC2vO31f https://t.co/pAknsSnnNT
Links:
Dr. John Cush RheumNow ( View Tweet)
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults based on induction studies, U-EXCEED, U-EXCEL,& U-ENDURE maintenance study. This is 7th FDA approval for RINVOQ https://t.co/JFyiETe43S https://t.co/zGJKZ3l0d4
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us for the final Tuesday Night Rheumatology of May.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Methotrexate Use: 50 Yr. Perspective
Myths vs Reality in RA
Biosimilars - Back on the Agenda
https://t.co/cqFNCRlGym https://t.co/fNS6cGBuDB
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for:
-KOL perspective videos
-Clinical Trial Highlights
-Daily Faculty Recaps
-Live Streaming
and more! https://t.co/uR4ZwnPGiF
Dr. John Cush RheumNow ( View Tweet)
Ph 3 study 800 ICU pts w/ severe community acq pneumonia shows those on IV hydrocortisone had lower mortality at day 28 (6.2% vs 11.9%; P=0.006), less intubation (18% vs 29.5%), less vasopressors (15% v 25%) vs PBO; no Diff w/ infx rates or GI bleed https://t.co/BjIM8UJXZS https://t.co/389CZovrZm
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch our video presented by leading expert Dr. Michelle Petri to learn why complete renal response matters in #LupusNephritis. #SponsoredbyGSKUSMA
https://t.co/XFZH5HprH4 https://t.co/PYfHy6uoZt
Links:
Dr. John Cush RheumNow ( View Tweet)
AxSpA is primarily a genetic disease
- clusters in families, especially HLA-B27+ first degree relatives
- genetic testing for asymptomatic relatives not recommended
@RheumNow #RNL2023 https://t.co/WeNApLE5to https://t.co/zDzHfdmpCG
Links:
Dr. John Cush RheumNow ( View Tweet)
⚠️Beware not all bone marrow oedema =#AxSpA on MRI !
Signal seen in 17% volunteers at SIJs
@DrPoddubnyy
#RNL2023 https://t.co/c4gqnBzdnO https://t.co/kZiX8r62aY
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk of familial AS is 19.4%, Reveille #RNL2023 @RheumNow https://t.co/7CzaXgqkPG https://t.co/KrmKGblVmd
Links:
Dr. John Cush RheumNow ( View Tweet)